Janux Therapeutics Inc
NASDAQ:JANX

Watchlist Manager
Janux Therapeutics Inc Logo
Janux Therapeutics Inc
NASDAQ:JANX
Watchlist
Price: 15.58 USD -1.02% Market Closed
Market Cap: 937.1m USD

Wall Street
Price Targets

JANX Price Targets Summary
Janux Therapeutics Inc

Wall Street analysts forecast JANX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JANX is 69.3 USD with a low forecast of 32.32 USD and a high forecast of 210 USD.

Lowest
Price Target
32.32 USD
107% Upside
Average
Price Target
69.3 USD
345% Upside
Highest
Price Target
210 USD
1 248% Upside
Janux Therapeutics Inc Competitors:
Price Targets
302440
SK Bioscience Co Ltd
25% Downside
KALV
Kalvista Pharmaceuticals Inc
88% Upside
VCYT
Veracyte Inc
14% Upside
CUV
Clinuvel Pharmaceuticals Ltd
106% Upside
IMDX
Insight Molecular Diagnostics Inc
40% Upside
UTHR
United Therapeutics Corp
7% Upside
6160
Beigene Ltd
38% Upside

Revenue
Forecast

Revenue Estimate
Janux Therapeutics Inc

The compound annual growth rate of Janux Therapeutics Inc's revenue for the next 3 years is -21%.

N/A
Past Growth
-21%
Estimated Growth
Estimates Accuracy
27%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Janux Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Janux Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is JANX's stock price target?
Price Target
69.3 USD

According to Wall Street analysts, the average 1-year price target for JANX is 69.3 USD with a low forecast of 32.32 USD and a high forecast of 210 USD.

What is Janux Therapeutics Inc's Revenue forecast?
Projected CAGR
-21%

The compound annual growth rate of Janux Therapeutics Inc's revenue for the next 3 years is -21%.

Back to Top